All In Biotech

Drug Trial Radar · NCT06948214

Phase 3 Study of LUM-201 in Children With Growth Hormone Deficiency

A Multicenter, 12-Month, Randomized, Double Blind, Placebo-Controlled Phase 3 Efficacy and Safety Study of Daily Oral LUM-201 in Naïve-to-Treatment, Prepubertal Children With Growth Hormone Deficiency (GHD)

Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

May 20, 2026

Primary completion

Dec 2027

Study completion Jan 2028

Sponsor

Lead sponsor
Lumos PharmaIndustry
Sponsor type
Industry
First posted
Apr 29, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 3 years, up to 11 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The OraGrowtH Phase 3 Trial is a multi-national trial. The goals of the trial are to study LUM-201 as a treatment for Pediatric Growth Hormone Deficiency (PGHD) in naive to treatment children and validate the LUM-201 predictive enrichment marker (LUM-201 PEM) strategy to select subjects likely to respond to therapy with daily oral LUM-201.

Conditions

  • Growth Hormone Deficiency (GHD)

Interventions

  • LUM-201Drug

    1.6 mg/kg/day, administered orally once daily

  • Matched Placebo (Capsules)Other

    Administered orally once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. AHV after 12 months on LUM-201 compared to placeboTime frame: Day 1 to Month 12

Locations

55 sites in 8 countries. Site status is shown where the registry gives one.

  • Lumos Pharma Investigational Site

    Birmingham, Alabama · Recruiting

  • Lumos Pharma Investigational Site

    Madera, California · Recruiting

  • Lumos Pharma Investigational Site

    Orange, California · Recruiting

  • Lumos Pharma Investigational Site

    Sacramento, California · Recruiting

  • Lumos Pharma Investigational Site

    San Diego, California · Recruiting

  • Lumos Pharma Investigational Site

    Centennial, Colorado · Recruiting

  • Lumos Pharma Investigational Site

    Greenwood Village, Colorado · Recruiting

  • Lumos Pharma Investigational Site

    Washington D.C., District of Columbia · Recruiting

  • Lumos Pharma Investigational Site

    Hollywood, Florida · Recruiting

  • Lumos Pharma Investigational Site

    Jacksonville, Florida · Recruiting

  • Lumos Pharma Investigational Site

    Miami, Florida · Recruiting

  • Lumos Pharma Investigational Site

    Orlando, Florida · Recruiting

  • Lumos Pharma Investigational Site

    Tallahassee, Florida · Recruiting

  • Lumos Pharma Investigational Site

    Savannah, Georgia · Recruiting

  • Lumos Pharma Investigational Site

    Indianapolis, Indiana · Recruiting

  • Lumos Pharma Investigational Site

    Iowa City, Iowa · Recruiting

  • Lumos Pharma Investigational Site

    New Orleans, Louisiana · Recruiting

  • Lumos Pharma Investigational Site

    Minneapolis, Minnesota · Recruiting

  • Lumos Pharma Investigational Site

    Kansas City, Missouri · Recruiting

  • Lumos Pharma Investigational Site

    Las Vegas, Nevada · Recruiting

  • Lumos Pharma Investigational Site

    New Brunswick, New Jersey · Recruiting

  • Lumos Pharma Investigational Site

    Staten Island, New York · Recruiting

  • Lumos Pharma Investigational Site

    Columbus, Ohio · Recruiting

  • Lumos Pharma Investigational Site

    Oklahoma City, Oklahoma · Recruiting

  • Lumos Pharma Investigational Site

    Columbia, South Carolina · Recruiting

  • Lumos Pharma Investigational Site

    Amarillo, Texas · Recruiting

  • Lumos Pharma Investigational Site

    Corpus Christi, Texas · Recruiting

  • Lumos Pharma Investigational Site

    Fort Worth, Texas · Recruiting

  • Lumos Pharma Investigational Site

    San Antonio, Texas · Recruiting

  • Lumos Pharma Investigational Site

    Charlottesville, Virginia · Recruiting

  • Lumos Pharma Investigational Site

    Seattle, Washington · Recruiting

  • Lumos Pharma Investigational Site

    San Miguel de Tucumán, Tucumán Province, Argentina · Recruiting

  • Children's Health Queensland Hospital and Health Service

    South Brisbane, Queensland, Australia · Recruiting

  • Lumos Pharma Investigational Site

    Clayton, Victoria, Australia · Recruiting

  • Lumos Pharma Investigational Site

    Parkville, Victoria, Australia · Recruiting

  • Lumos Pharma Investigational Site

    Santiago, Santiago Metropolitan, Chile · Recruiting

  • Lumos Pharma Investigational Site

    Chandigarh, India · Recruiting

  • Lumos Pharma Investigational Site

    Mumbai, Maharashtra, India · Recruiting

  • Lumos Pharma Investigational Site

    Nashik, Maharashtra, India · Recruiting

  • Lumos Pharma Investigational Site

    Jaipur, Rajasthan, India · Recruiting

Showing 40 of 55 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.